Publications by authors named "Anouk E de Wit"

Article Synopsis
  • Oral contraceptives (OCs) are widely used for birth control but may be linked to increased symptoms of depression and insomnia, especially in women with a history of depression.
  • This study aimed to explore the relationship between OC use and symptoms of major depressive disorder (MDD), dysthymia, and insomnia among adult women, examining whether prior depression influences these symptoms during OC use.
  • Results from a sample of over 2,000 measurements indicated that OC use did not significantly correlate with heightened severity of depressive or insomnia symptoms when compared to women who cycle naturally without OCs.
View Article and Find Full Text PDF

Background: Because of the widespread use of oral contraceptives (OCs) and the devastating effects of depression both on an individual and a societal level, it is crucial to understand the nature of the previously reported relationship between OC use and depression risk. Insight into the impact of analytical choices on the association is important when interpreting available evidence. Hence, we examined the association between adolescent OC use and subsequent depression risk in early adulthood analyzing all theoretically justifiable models.

View Article and Find Full Text PDF

Objective: Combined oral contraceptives are often considered a treatment option for women with premenstrual syndrome or premenstrual dysphoric disorder also seeking contraception, but evidence for this treatment is scarce. We aimed to determine (1) the level of evidence for the efficacy of combined oral contraceptives in managing premenstrual depressive symptoms and overall premenstrual symptomatology and (2) the comparative efficacy of combined oral contraceptives (the International Prospective Register of Systematic Reviews registration number CRD42020205510).

Data Sources: We searched Cochrane Central Register of Controlled Trials, PubMed, Web of Science, PsycINFO, EMCare, and Embase from inception to June 3, 2021.

View Article and Find Full Text PDF

Background: Observational studies suggest that hormonal contraceptive use may increase depressive symptoms in women, but it is unclear whether the effect is causal.

Aims: To quantitatively examine the evidence from randomised clinical trials for the link between hormonal contraceptive use and depressive symptoms.

Method: We performed a systematic review and network meta-analysis of randomised clinical trials comparing women randomised to any form of a hormonal contraceptive with women randomised to any other form of a (non-)hormonal contraceptive or placebo.

View Article and Find Full Text PDF

Background: Hypoandrogenic men showed a higher prevalence of major depressive disorder (MDD), which could be ascribed to overlapping symptoms such as sexual dysfunction, or additionally to core emotional symptoms such as sadness and anhedonia. We examined whether androgen levels 1) differ between men with and without MDD cross-sectionally, 2) are associated with an elevated risk for onset of MDD prospectively, and 3) associate with all individual MDD symptoms, or only with hypogonadism overlapping symptoms.

Methods: In 823 men (mean age 43.

View Article and Find Full Text PDF
Article Synopsis
  • Immune checkpoint inhibitors (ICI) are beneficial for cancer patients, including those with brain metastases (BMs), but the interaction with steroids is unclear.
  • A systematic literature review analyzed data from 15 studies involving 1102 BM patients, with 32.1% using steroids, revealing worse overall survival (OS) and progression-free survival (PFS) for the steroid group compared to those not using steroids.
  • The findings highlight the need for further research on how steroids affect treatment outcomes in BM patients receiving ICI, particularly regarding dosage and timing.
View Article and Find Full Text PDF

Major depressive disorder (MDD) has a higher prevalence in women with supraphysiologic androgen levels. Whether there is also an association between depression and androgen levels in the physiological range, is unknown. This study examined if women with current MDD have higher androgen levels compared to women who have never had MDD, and if androgen levels are associated with onset and remission of MDD.

View Article and Find Full Text PDF

Objective: Irritability is a highly burdensome complaint, commonly, but not universally, linked with depressive symptoms. While increased variability in estradiol has been associated with depressive symptoms during perimenopause, more insight is needed into reproductive hormone dynamics and other factors that predispose perimenopausal women to irritable mood.

Methods: Among 50 mildly depressed perimenopausal women (mean (SD) age 48.

View Article and Find Full Text PDF

Importance: Oral contraceptives have been associated with an increased risk of subsequent clinical depression in adolescents. However, the association of oral contraceptive use with concurrent depressive symptoms remains unclear.

Objectives: To investigate the association between oral contraceptive use and depressive symptoms and to examine whether this association is affected by age and which specific symptoms are associated with oral contraceptive use.

View Article and Find Full Text PDF

Objectives: Older age and major depressive disorder (MDD) are both risk factors for the development of cardiovascular diseases. Testosterone has been associated with MDD and metabolic syndrome (MetS) in men, although associations in women are less clear. Therefore, we investigated whether testosterone is associated with MetS and whether this association is different for depressed and non-depressed older men and women.

View Article and Find Full Text PDF